Market Research Report
GLOBAL ATOPIC DERMATITIS DRUGS MARKET FORECAST 2018-2026
|Published by||Inkwood Research||Product code||626309|
|Published||Content info||121 Pages
Delivery time: 1-2 business days
|GLOBAL ATOPIC DERMATITIS DRUGS MARKET FORECAST 2018-2026|
|Published: April 16, 2018||Content info: 121 Pages||
The Atopic Dermatitis Drugs global market is growing at 4.66% of CAGR over the forecasting years. Growing incidences of allergies due to particular foods is the major factor augmenting the market growth globally.
Atopic Dermatitis is a skin disease also known as chronic eczematous. The symptoms of this disease vary person to person. However, some of its common symptoms are inflamed and itchy skin that causes crackling, minute blisters, swelling, scaling, and crusting. The global Atopic Dermatitis drugs market comprise of two segments route of administration and drug class. The topical segment holds the highest share in the Atopic Dermatitis Drugs route of administration market. The interleukin inhibitor segment is anticipated to generate the highest revenue in the Atopic Dermatitis drug class market. The global Atopic Dermatitis Drugs market is highly generic which creates a lot of challenges in the growth of the market globally.
The Atopic Dermatitis Drugs market is segmented in four key geographies like North America, Europe, Asia Pacific, and rest of world. North America is the global leader in the Atopic Dermatitis Drugs market. Growing allergies is the key reasons for the growth of this market in the North American region. Europe Atopic Dermatitis Drugs market continues to escalate in terms of revenue majorly due to the rising awareness among the population. Atopic Dermatitis is highly prevalent in APAC region. It is the second largest Atopic Dermatitis Drugs market during the forecasting years. It is also the most common skin disease in the region, so the demand for the market is highest in APAC region.
The established players in the market are Allergan Plc., Aqua Pharmaceuticals (An Almirall Company), Astellas Pharma Inc., Bayer Ag, Biofrontera Ag, Bristol-Myers Squibb, Stiefel Laboratories Inc., Encore Dermatology, Galderma Sa, Leo Pharma, Meda Pharmaceuticals (Mylan), Novartis Ag, Pfizer, Regeneron Pharmaceuticals, Sanofi Sa, and Valent Pharmaceutical Inc.